miR-155 promotes FLT3-ITD-induced myeloproliferative disorder through inhibition of the interferon (IFN) response, inositol 5-phosphatase 1 (SHIP1), CEBPB, and PU.1, while it is upregulated in FLT3-ITD+ and MLL-rearranged AML (57, 77–80). Here, KMT2A is linked to acute myeloid leukemia.